Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 276

1.

A prospective study of fatigue trajectories among in-centre haemodialysis patients.

Picariello F, Norton S, Moss-Morris R, Macdougall IC, Chilcot J.

Br J Health Psychol. 2020 Feb;25(1):61-88. doi: 10.1111/bjhp.12395. Epub 2019 Nov 19.

PMID:
31742834
2.

Iron Regulation by Molidustat, a Daily Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor, in Patients with Chronic Kidney Disease.

Akizawa T, Macdougall IC, Berns JS, Yamamoto H, Taguchi M, Iekushi K, Bernhardt T.

Nephron. 2019;143(4):243-254. doi: 10.1159/000502012. Epub 2019 Aug 6.

3.

Restricting Red-Cell Transfusions in Cardiac Surgery: No Increase in AKI.

Macdougall IC, Richards T.

J Am Soc Nephrol. 2019 Jul;30(7):1143-1144. doi: 10.1681/ASN.2019050509. Epub 2019 Jun 20. No abstract available.

PMID:
31221680
4.

Intravenous Iron and Maintenance Hemodialysis. Reply.

Macdougall IC, Ford I.

N Engl J Med. 2019 Jun 13;380(24):e46. doi: 10.1056/NEJMc1902945. No abstract available.

PMID:
31189054
5.

Intravenous Iron Use in the Care of Patients with Kidney Disease.

Macdougall IC.

Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1528-1530. doi: 10.2215/CJN.00510119. Epub 2019 Jun 7. No abstract available.

PMID:
31175103
6.

Obesity and recovery from acute kidney injury (Ob AKI): a prospective cohort feasibility study.

MacLaughlin HL, Blacklock RM, Wright K, Pot G, Jayawardene S, McIntyre CW, Macdougall IC, Selby NM.

BMJ Open. 2019 Mar 20;9(3):e024033. doi: 10.1136/bmjopen-2018-024033.

7.

Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.

Akizawa T, Macdougall IC, Berns JS, Bernhardt T, Staedtler G, Taguchi M, Iekushi K, Krueger T.

Am J Nephrol. 2019;49(4):271-280. doi: 10.1159/000499111. Epub 2019 Mar 8. Erratum in: Am J Nephrol. 2019;50(2):160.

8.

Ferumoxytol for iron deficiency anemia in patients undergoing hemodialysis. The FACT randomized controlled trial
.

Macdougall IC, Strauss WE, Dahl NV, Bernard K, Li Z.

Clin Nephrol. 2019 Apr;91(4):237-245. doi: 10.5414/CN109512.

9.

Erratum.

Greenwood SA, Castle E, Lindup H, Mayes J, Waite I, Grant D, Mangahis E, Crabb O, Shevket K, Macdougall IC, MacLaughlin HL.

Nephrol Dial Transplant. 2019 Feb 15. pii: gfz032. doi: 10.1093/ndt/gfz032. [Epub ahead of print] No abstract available.

PMID:
30770707
10.

New options for the anemia of chronic kidney disease.

Coyne DW, Goldsmith D, Macdougall IC.

Kidney Int Suppl (2011). 2017 Dec;7(3):157-163. doi: 10.1016/j.kisu.2017.09.002. Epub 2017 Nov 17. Review.

11.

Treatment of anaemia in end-stage renal disease: A double-edged iron sword?

Chinnadurai R, Macdougall IC, Kalra PA.

EBioMedicine. 2019 Feb;40:31-32. doi: 10.1016/j.ebiom.2019.01.005. Epub 2019 Jan 17. No abstract available.

12.

Effects of Molidustat in the Treatment of Anemia in CKD.

Macdougall IC, Akizawa T, Berns JS, Bernhardt T, Krueger T.

Clin J Am Soc Nephrol. 2019 Jan 7;14(1):28-39. doi: 10.2215/CJN.02510218. Epub 2018 Dec 17. Erratum in: Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1524.

13.

Randomized trial of intravenous iron-induced hypophosphatemia.

Wolf M, Chertow GM, Macdougall IC, Kaper R, Krop J, Strauss W.

JCI Insight. 2018 Dec 6;3(23). pii: 124486. doi: 10.1172/jci.insight.124486.

14.

Mortality and morbidity following exercise-based renal rehabilitation in patients with chronic kidney disease: the effect of programme completion and change in exercise capacity.

Greenwood SA, Castle E, Lindup H, Mayes J, Waite I, Grant D, Mangahis E, Crabb O, Shevket K, Macdougall IC, MacLaughlin HL.

Nephrol Dial Transplant. 2019 Apr 1;34(4):618-625. doi: 10.1093/ndt/gfy351.

15.

Intravenous Iron in Patients Undergoing Maintenance Hemodialysis.

Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Tomson CRV, Wheeler DC, Winearls CG, Ford I; PIVOTAL Investigators and Committees.

N Engl J Med. 2019 Jan 31;380(5):447-458. doi: 10.1056/NEJMoa1810742. Epub 2018 Oct 26. Erratum in: N Engl J Med. 2019 Jan 14;:.

PMID:
30365356
16.

Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data.

Macdougall IC, White C, Anker SD, Bhandari S, Farrington K, Kalra PA, McMurray JJV, Murray H, Steenkamp R, Tomson CRV, Wheeler DC, Winearls CG, Ford I; on behalf of the PIVOTAL Trial investigators.

Am J Nephrol. 2018;48(4):260-268. doi: 10.1159/000493551. Epub 2018 Oct 10.

17.

Investigating Serious Adverse Drug Reactions in Patients Receiving Erythropoiesis-Stimulating Agents: A Root Cause Analysis Using the "ANTICIPATE" Framework.

Jacob S, Nichols J, Macdougall IC, Qureshi Z, Chen B, Yang YT, Norris LB, Bennett CL.

Am J Ther. 2018 Nov/Dec;25(6):e670-e674. doi: 10.1097/MJT.0000000000000768.

PMID:
30169374
18.

Fatigue in Prevalent Haemodialysis Patients Predicts All-cause Mortality and Kidney Transplantation.

Picariello F, Norton S, Moss-Morris R, Macdougall IC, Chilcot J.

Ann Behav Med. 2019 May 3;53(6):501-514. doi: 10.1093/abm/kay061.

PMID:
30020399
19.

A response by Strauss et al. to "a comment on the comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia".

Strauss WE, Franklin Adkinson N, Macdougall IC, Auerbach M, Kaper RF, Chertow GM, Krop JS.

Am J Hematol. 2018 Sep;93(9):E232-E233. doi: 10.1002/ajh.25200. Epub 2018 Aug 6. No abstract available.

20.

Iron therapy for managing anaemia in chronic kidney disease.

Macdougall IC.

Curr Opin Nephrol Hypertens. 2018 Sep;27(5):358-363. doi: 10.1097/MNH.0000000000000436. Review.

PMID:
29905580
21.
22.

HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.

Kular D, Macdougall IC.

Pediatr Nephrol. 2019 Mar;34(3):365-378. doi: 10.1007/s00467-017-3849-3. Epub 2018 Mar 22. Review.

23.

Cognitive-behavioural therapy (CBT) for renal fatigue (BReF): a feasibility randomised-controlled trial of CBT for the management of fatigue in haemodialysis (HD) patients.

Picariello F, Moss-Morris R, Macdougall IC, Norton S, Da Silva-Gane M, Farrington K, Clayton H, Chilcot J.

BMJ Open. 2018 Mar 8;8(3):e020842. doi: 10.1136/bmjopen-2017-020842.

24.

Positive Iron Balance in Chronic Kidney Disease: How Much is Too Much and How to Tell?

Wish JB, Aronoff GR, Bacon BR, Brugnara C, Eckardt KU, Ganz T, Macdougall IC, Núñez J, Perahia AJ, Wood JC.

Am J Nephrol. 2018;47(2):72-83. doi: 10.1159/000486968. Epub 2018 Feb 13. Review.

25.

Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.

Adkinson NF, Strauss WE, Macdougall IC, Bernard KE, Auerbach M, Kaper RF, Chertow GM, Krop JS.

Am J Hematol. 2018 May;93(5):683-690. doi: 10.1002/ajh.25060. Epub 2018 Feb 24.

26.

Intravenous iron: out of sight, out of mind.

Auerbach M, Muñoz M, Macdougall IC.

Lancet Haematol. 2018 Jan;5(1):e10-e12. doi: 10.1016/S2352-3026(17)30230-2. No abstract available.

PMID:
29304320
27.

'It's when you're not doing too much you feel tired': A qualitative exploration of fatigue in end-stage kidney disease.

Picariello F, Moss-Morris R, Macdougall IC, Chilcot J.

Br J Health Psychol. 2018 May;23(2):311-333. doi: 10.1111/bjhp.12289. Epub 2017 Dec 27.

28.

Intravenous iron therapy in patients with chronic kidney disease: recent evidence and future directions.

Macdougall IC.

Clin Kidney J. 2017 Dec;10(Suppl 1):i16-i24. doi: 10.1093/ckj/sfx043. Epub 2017 Nov 28. Review.

29.

A controlled study of the effects of ferric carboxymaltose on bone and haematinic biomarkers in chronic kidney disease and pregnancy.

Huang LL, Lee D, Troster SM, Kent AB, Roberts MA, Macdougall IC, McMahon LP.

Nephrol Dial Transplant. 2018 Sep 1;33(9):1628-1635. doi: 10.1093/ndt/gfx310.

PMID:
29165637
30.

Erythropoietic response to oral iron in patients with nondialysis-dependent chronic kidney disease in the FIND-CKD trial
.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Wyck DV, Meier Y, Larroque S, Perrin A, Roger SD.

Clin Nephrol. 2017 Dec;88(12):301-310. doi: 10.5414/CN109198.

31.

Correction to: Psychosocial and Clinical Correlates of Fatigue in Haemodialysis Patients: the Importance of Patients' Illness Cognitions and Behaviours.

Chilcot J, Moss-Morris R, Artom M, Harden L, Picariello F, Hughes H, Bates S, Macdougall IC.

Int J Behav Med. 2017 Dec;24(6):958. doi: 10.1007/s12529-017-9692-x.

PMID:
29058122
32.
33.

Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.

van Veldhuisen DJ, Ponikowski P, van der Meer P, Metra M, Böhm M, Doletsky A, Voors AA, Macdougall IC, Anker SD, Roubert B, Zakin L, Cohen-Solal A; EFFECT-HF Investigators.

Circulation. 2017 Oct 10;136(15):1374-1383. doi: 10.1161/CIRCULATIONAHA.117.027497. Epub 2017 Jul 12.

34.

The role of psychological factors in fatigue among end-stage kidney disease patients: a critical review.

Picariello F, Moss-Morris R, Macdougall IC, Chilcot AJ.

Clin Kidney J. 2017 Feb;10(1):79-88. doi: 10.1093/ckj/sfw113. Epub 2016 Dec 20.

35.

Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management.

Cappellini MD, Comin-Colet J, de Francisco A, Dignass A, Doehner W, Lam CS, Macdougall IC, Rogler G, Camaschella C, Kadir R, Kassebaum NJ, Spahn DR, Taher AT, Musallam KM; IRON CORE Group.

Am J Hematol. 2017 Oct;92(10):1068-1078. doi: 10.1002/ajh.24820. Epub 2017 Jul 7. Review.

36.

IL-2 therapy restores regulatory T-cell dysfunction induced by calcineurin inhibitors.

Whitehouse G, Gray E, Mastoridis S, Merritt E, Kodela E, Yang JHM, Danger R, Mairal M, Christakoudi S, Lozano JJ, Macdougall IC, Tree TIM, Sanchez-Fueyo A, Martinez-Llordella M.

Proc Natl Acad Sci U S A. 2017 Jul 3;114(27):7083-7088. doi: 10.1073/pnas.1620835114. Epub 2017 Jun 5.

37.
38.

Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.

Roger SD, Gaillard CA, Bock AH, Carrera F, Eckardt KU, Van Wyck DB, Cronin M, Meier Y, Larroque S, Macdougall IC; FIND-CKD Study Investigators.

Nephrol Dial Transplant. 2017 Sep 1;32(9):1530-1539. doi: 10.1093/ndt/gfw264.

39.

Examining the efficacy of social-psychological interventions for the management of fatigue in end-stage kidney disease (ESKD): a systematic review with meta-analysis.

Picariello F, Hudson JL, Moss-Morris R, Macdougall IC, Chilcot J.

Health Psychol Rev. 2017 Jun;11(2):197-216. doi: 10.1080/17437199.2017.1298045. Epub 2017 Mar 6. Review.

PMID:
28277013
40.

Prophylactic Ureteric Stents in Renal Transplant Recipients: A Multicenter Randomized Controlled Trial of Early Versus Late Removal.

Patel P, Rebollo-Mesa I, Ryan E, Sinha MD, Marks SD, Banga N, Macdougall IC, Webb MC, Koffman G, Olsburgh J.

Am J Transplant. 2017 Aug;17(8):2129-2138. doi: 10.1111/ajt.14223. Epub 2017 Mar 17.

41.

Long-term pulse wave velocity outcomes with aerobic and resistance training in kidney transplant recipients - A pilot randomised controlled trial.

O'Connor EM, Koufaki P, Mercer TH, Lindup H, Nugent E, Goldsmith D, Macdougall IC, Greenwood SA.

PLoS One. 2017 Feb 3;12(2):e0171063. doi: 10.1371/journal.pone.0171063. eCollection 2017.

42.

Targeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients.

Locatelli F, Fishbane S, Block GA, Macdougall IC.

Am J Nephrol. 2017;45(3):187-199. doi: 10.1159/000455166. Epub 2017 Jan 25. Review.

43.

Renal function in patients with non-dialysis chronic kidney disease receiving intravenous ferric carboxymaltose: an analysis of the randomized FIND-CKD trial.

Macdougall IC, Bock AH, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Meier Y, Larroque S, Roger SD; FIND-CKD Study investigators.

BMC Nephrol. 2017 Jan 17;18(1):24. doi: 10.1186/s12882-017-0444-6.

44.

Dental Attendance and Self-reported Oral Health Status of Renal Dialysis Patients: A Comparison of Results with the UK Adult Dental Health Survey.

Djemal S, Rumjon A, Macdougall IC, Singh P, Warnakulasuriya S.

Oral Health Prev Dent. 2016;14(6):529-534. doi: 10.3290/j.ohpd.a37138.

PMID:
27957563
45.

Complement Activation-Related Pseudo-Allergy: A Fresh Look at Hypersensitivity Reactions to Intravenous Iron.

Macdougall IC, Vernon K.

Am J Nephrol. 2017;45(1):60-62. doi: 10.1159/000451069. Epub 2016 Nov 29. No abstract available.

46.

Effects of intravenous iron on fibroblast growth factor 23 (FGF23) in haemodialysis patients: a randomized controlled trial.

Roberts MA, Huang L, Lee D, MacGinley R, Troster SM, Kent AB, Bansal SS, Macdougall IC, McMahon LP.

BMC Nephrol. 2016 Nov 16;17(1):177.

47.

Does Intragastric Balloon Treatment for Obesity in Chronic Kidney Disease Heighten Acute Kidney Injury Risk?

MacLaughlin HL, Macdougall IC, Hall WL, Dew T, Mantzoukis K, Oben JA.

Am J Nephrol. 2016;44(6):411-418. Epub 2016 Oct 27.

PMID:
27784008
48.

Oral Iron Therapy: After Three Centuries, It Is Time for a Change.

Auerbach M, Macdougall IC.

Am J Kidney Dis. 2016 Nov;68(5):665-666. doi: 10.1053/j.ajkd.2016.08.007. No abstract available.

PMID:
27772628
49.

Intravenous iron and erythropoiesis-stimulating agents in haemodialysis: A systematic review and meta-analysis.

Roger SD, Tio M, Park HC, Choong HL, Goh B, Cushway TR, Stevens V, Macdougall IC.

Nephrology (Carlton). 2017 Dec;22(12):969-976. doi: 10.1111/nep.12940. Review.

50.

Peginesatide for the treatment of anemia due to chronic kidney disease - an unfulfilled promise.

Hermanson T, Bennett CL, Macdougall IC.

Expert Opin Drug Saf. 2016 Oct;15(10):1421-6. doi: 10.1080/14740338.2016.1218467. Epub 2016 Aug 23. Review.

Supplemental Content

Loading ...
Support Center